Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Adlai Nortye logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately bullish: Seven analysts rate ANL a “Moderate Buy”—five buy, one strong buy and one sell—with an average 1-year price target of $29.50.
  • ANL opened at $8.74 after a reported 7.8% decline; its 50-day and 200-day moving averages were $12.68 and $11.69, respectively.
  • Insiders sold 26,881 shares worth about $411,060 over the past 90 days, while institutional investors and hedge funds own 35.21% of the stock.
  • Five stocks we like better than Adlai Nortye.

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $29.50.

Several brokerages recently issued reports on ANL. Weiss Ratings reissued a "sell (e+)" rating on shares of Adlai Nortye in a report on Monday, October 12th. Wall Street Zen cut shares of Adlai Nortye from a "buy" rating to a "hold" rating in a research note on Saturday, October 31st. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Adlai Nortye in a report on Tuesday, September 8th. Loop Capital set a $49.00 price objective on shares of Adlai Nortye in a report on Tuesday, September 8th. Finally, Jefferies Financial Group upgraded shares of Adlai Nortye to a "strong-buy" rating in a research note on Monday, October 5th.

Get Our Latest Report on ANL

Adlai Nortye Stock Down 7.8%

ANL opened at $8.74 on Thursday. The firm's 50-day simple moving average is $12.68 and its 200-day simple moving average is $11.69. Adlai Nortye has a twelve month low of $0.88 and a twelve month high of $17.25.

Insider Buying and Selling

In other Adlai Nortye news, CFO Xiaofeng Ye sold 5,667 shares of Adlai Nortye stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the transaction, the chief financial officer owned 147,757 shares in the company, valued at approximately $2,105,537.25. The trade was a 3.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the business's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the completion of the transaction, the director directly owned 121,453 shares in the company, valued at approximately $1,942,033.47. This represents a 7.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 26,881 shares of company stock worth $411,060.

Institutional Trading of Adlai Nortye

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Soleus Capital Management L.P. raised its holdings in shares of Adlai Nortye by 213.8% in the third quarter. Soleus Capital Management L.P. now owns 1,272,355 shares of the company's stock valued at $20,358,000 after buying an additional 866,832 shares during the last quarter. Braidwell LP acquired a new position in Adlai Nortye during the 2nd quarter worth about $9,145,000. Boone Capital Management LLC bought a new stake in Adlai Nortye during the 2nd quarter worth about $2,971,000. Affinity Asset Advisors LLC bought a new stake in Adlai Nortye during the 1st quarter worth about $1,140,000. Finally, ADAR1 Capital Management LLC bought a new stake in Adlai Nortye during the 1st quarter worth about $816,000. 35.21% of the stock is currently owned by institutional investors and hedge funds.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2004 and headquartered in Hangzhou, China, the company conducts drug research and development for potential use in China and international markets. Its investigational oncology pipeline includes AN2025, a pan-RAF inhibitor; AN0025, an EP4 antagonist; and AN4005, an adenosine A2A/A2B receptor antagonist. These candidates are being studied for their potential to treat solid tumors, including in combination with other cancer therapies.

Further Reading

Analyst Recommendations for Adlai Nortye (NASDAQ:ANL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Adlai Nortye Right Now?

Before you consider Adlai Nortye, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.

While Adlai Nortye currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines